Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC
Introduction: Patients with EGFR-mutant NSCLC have a high incidence of brain metastases. The EGFR-directed tyrosine kinase inhibitor osimertinib has intracranial activity, making the role of local central nervous system (CNS)-directed therapies, such as radiation and surgery, less clear. Methods: Pa...
Main Authors: | Brandon S. Imber, MD, MA, Ryka Sehgal, MD, Rachel Saganty, MD, Anne S. Reiner, MPH, A. Turan Ilica, MD, Emily Miao, PharmD, Bob T. Li, MD, Gregory J. Riely, MD, Helena A. Yu, MD, Katherine S. Panageas, DrPH, Robert J. Young, MD, Luke R.G. Pike, MD, DPhil, Nelson S. Moss, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | JTO Clinical and Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323001509 |
Similar Items
-
Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01) -
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
by: Judith L. Gulikers, MSc, et al.
Published: (2024-04-01) -
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01) -
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01) -
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)